Ethocle Reports has published its latest Market Research Report on Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies. Browse market data tables and figures.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Movers & shakers interview with vivek trikha head diagnostics onc quest ...oncquest
OncQuest Laboratories Limited (formerly Dabur OncQuest) formally announced its existence as an independent entity, moving away from being a part of Dabur Pharma Limited, on December 31, 2007. OncQuest Laboratories Limited was incorporated in January 2008.
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.
Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.
Business Transformation and Partnering Strategies to Accelerate Commercialisa...Oxford Global
Magda Papadaki PhD, former Head of Manufacturing & Innovation, Association of the British Pharmaceutical Industry (ABPI) and current Associate Director, MSD shares her recent presentation at London's Cell & Gene Therapy Congress 2018, “Business Transformation and Partnering Strategies to Accelerate Commercialisation of Cell & Gene Therapies.”
The presentation includes key information and insights into:
- New Pathways to CGT commercialisation and clinical use
- System Readiness: New Pathways & Collaborations
- Innovating how we Innovate to Deliver Cures.
More information about the 2019 Cell & Gene Therapy Congress can be found here: www.celltherapy-congress.com
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Movers & shakers interview with vivek trikha head diagnostics onc quest ...oncquest
OncQuest Laboratories Limited (formerly Dabur OncQuest) formally announced its existence as an independent entity, moving away from being a part of Dabur Pharma Limited, on December 31, 2007. OncQuest Laboratories Limited was incorporated in January 2008.
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.
Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.
Business Transformation and Partnering Strategies to Accelerate Commercialisa...Oxford Global
Magda Papadaki PhD, former Head of Manufacturing & Innovation, Association of the British Pharmaceutical Industry (ABPI) and current Associate Director, MSD shares her recent presentation at London's Cell & Gene Therapy Congress 2018, “Business Transformation and Partnering Strategies to Accelerate Commercialisation of Cell & Gene Therapies.”
The presentation includes key information and insights into:
- New Pathways to CGT commercialisation and clinical use
- System Readiness: New Pathways & Collaborations
- Innovating how we Innovate to Deliver Cures.
More information about the 2019 Cell & Gene Therapy Congress can be found here: www.celltherapy-congress.com
Epilepsy Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Op...IMARC Group
The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032.
More Info:- https://www.imarcgroup.com/epilepsy-drugs-market
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...David2591
Most up-to-date research on "Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments" to its huge collection of research reports.
The global acquired orphan blood diseases therapeutics market size reached US$ 8.12 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.34 Billion by 2028, exhibiting a growth rate (CAGR) of 8.30% during 2023-2028.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Download Global antibody drug conjugate market & pipeline insight2020KuicK Research
\" Global Antibody Drug Conjugate Market & Pipeline Insight 2020\" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Intratumoral Cancer Therapies Market 2023: Epidemiology, Industry Trends, Siz...frankmorgan27
The elevating prevalence of cancer and the inflating need for therapies that can deliver drugs directly to the tumor site, enabling the targeted treatment, are primarily stimulating the intratumoral cancer therapies market.
Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Co...Renub Research
Renub Research (http://www.renub.com/report/personalized-medicine-diagnostics-flow-cytometry-sepsis-immunos-routine-coagulation-psychiatric-disorders-tumor-markers-molecular-blood-typing-and-other-testing-116) has announced the addition of the "Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)" report to its offering
Febrile Neutropenia Market 2023: Epidemiology, Industry Trends, Size, Share A...frankmorgan27
The growing utilization of chemotherapy or radiation therapy, which can hinder the bone marrow’s ability to produce new blood cells, is primarily driving the febrile neutropenia market.
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...frankmorgan27
The rising instances of hematologic malignancies and the inflating need to treat these conditions using radiotherapy and chemotherapy are primarily driving the minimal residual disease market.
Global regenerative medicines market (technology, application and geography) ...Allied Market Research
Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.
Global regenerative medicines market (technology, application and geography) ...Debbie Shields
Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Malignant Pleural Mesothelioma Market 2023: Epidemiology, Industry Trends, Si...frankmorgan27
The elevating cases of exposure to asbestos fibers, which become lodged in the lining of the abdomen, lungs, or heart, and cause irritation and inflammation, are primarily augmenting the malignant pleural mesothelioma market.
Ethocle Reports has published its latest Market Research Report on Ventricular Assist Devices. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Epilepsy Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Op...IMARC Group
The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032.
More Info:- https://www.imarcgroup.com/epilepsy-drugs-market
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...David2591
Most up-to-date research on "Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments" to its huge collection of research reports.
The global acquired orphan blood diseases therapeutics market size reached US$ 8.12 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.34 Billion by 2028, exhibiting a growth rate (CAGR) of 8.30% during 2023-2028.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Download Global antibody drug conjugate market & pipeline insight2020KuicK Research
\" Global Antibody Drug Conjugate Market & Pipeline Insight 2020\" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Intratumoral Cancer Therapies Market 2023: Epidemiology, Industry Trends, Siz...frankmorgan27
The elevating prevalence of cancer and the inflating need for therapies that can deliver drugs directly to the tumor site, enabling the targeted treatment, are primarily stimulating the intratumoral cancer therapies market.
Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Co...Renub Research
Renub Research (http://www.renub.com/report/personalized-medicine-diagnostics-flow-cytometry-sepsis-immunos-routine-coagulation-psychiatric-disorders-tumor-markers-molecular-blood-typing-and-other-testing-116) has announced the addition of the "Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)" report to its offering
Febrile Neutropenia Market 2023: Epidemiology, Industry Trends, Size, Share A...frankmorgan27
The growing utilization of chemotherapy or radiation therapy, which can hinder the bone marrow’s ability to produce new blood cells, is primarily driving the febrile neutropenia market.
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...frankmorgan27
The rising instances of hematologic malignancies and the inflating need to treat these conditions using radiotherapy and chemotherapy are primarily driving the minimal residual disease market.
Global regenerative medicines market (technology, application and geography) ...Allied Market Research
Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.
Global regenerative medicines market (technology, application and geography) ...Debbie Shields
Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Malignant Pleural Mesothelioma Market 2023: Epidemiology, Industry Trends, Si...frankmorgan27
The elevating cases of exposure to asbestos fibers, which become lodged in the lining of the abdomen, lungs, or heart, and cause irritation and inflammation, are primarily augmenting the malignant pleural mesothelioma market.
Ethocle Reports has published its latest Market Research Report on Ventricular Assist Devices. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2016. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Transcatheter Heart Valves - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Rx-OTC Switch Opportunities : Trends in OTC, category analysis, case studies and future opportunities. This report takes an in-depth look at the market for Rx-OTC switches. It considers which categories have the most potential for switching, analyzing both past performance and expected future outcomes, and then examines specific candidates. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Paper and paperboard global industry guideNelson Permal
Ethocle Reports has published its latest Market Research Report on Paper and Paperboard Global Industry Guide_2016. Essential resource for top-line data and analysis covering the global paper and paperboard market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies. Browse market data tables and figures.
Otc pharmaceuticals global industry guideNelson Permal
Ethocle Reports has published its latest Market Research Report on OTC Pharmaceuticals Global Industry Guide_2016. Essential resource for top-line data and analysis covering the global otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on North America Computed Tomography (CT) Systems Market Outlook to 2022. Develop business strategies by identifying the key market segments poised for strong growth in the future. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Neurological Diagnostic Equipment - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Medical equipment monthly deals analysisNelson Permal
Ethocle Reports has published its latest Market Research Report on Medical Equipment Monthly Deals Analysis: November 2016 - M&A and Investment Trends. Enhance your decision making capability in a more rapid and time sensitive manner. Browse market data tables and figures.
Medical equipment monthly deals analysi1Nelson Permal
Ethocle Reports has published its latest Market Research Report on Medical Equipment Monthly Deals Analysis: November 2016 - M&A and Investment Trends. Enhance your decision making capability in a more rapid and time sensitive manner. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Hyperglycemia - Pipeline Review, H2 2016. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Browse market data tables and figures.
Healthcare providers global industry guideNelson Permal
Ethocle Reports has published its latest Market Research Report on Healthcare Providers Global Industry Guide_2016. Essential resource for top-line data and analysis covering the global healthcare providers market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2025. Develop business strategies by understanding the trends shaping and driving the global UC market. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US. Develop business strategies by understanding the trends shaping and driving the US healthcare market. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US. Develop business strategies by understanding the trends shaping and driving the US healthcare market. Browse market data tables and figures.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
FIA officials brutally tortured innocent and snatched 200 Bitcoins of worth 4...jamalseoexpert1978
Farman Ayaz Khattak and Ehtesham Matloob are government officials in CTW Counter terrorism wing Islamabad, in Federal Investigation Agency FIA Headquarters. CTW and FIA kidnapped crypto currency owner from Islamabad and snatched 200 Bitcoins those worth of 4 billion rupees in Pakistan currency. There is not Cryptocurrency Regulations in Pakistan & CTW is official dacoit and stealing digital assets from the innocent crypto holders and making fake cases of terrorism to keep them silent.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Organizational Change Leadership Agile Tour Geneve 2024
Anti
1. Anti-hypertensive TherapeuticsinAsia-PacificMarketsto2022 - Increasing Prevalence of
HypertensionDrivesMarket Growth despite WeakPipeline
Ethocle Reportshaspublished its latest MarketResearch Reporton Anti-hypertensiveTherapeuticsin
Asia-PacificMarkets to 2022. Understand thecurrentclinical and commercial landscapeby considering
diseasepathogenesis,diagnosis,prognosis,and thetreatmentoptionsavailableateach stageof
diagnosis,including a clinical comparison of marketed therapies. Browsemarketdata tablesand figures.
PublishedOn:01-Dec-2016 | Pages:110
Summary
Hypertensionisaseriousandcommonmedical conditioncharacterizedbyelevatedbloodpressure.Itis
commonlyseeninthe agingpopulation,andinpeople withsedentarylifestylesandobesity.Asone of
the most significantpreventablecausesof deathworldwide,early diagnosisof the conditioniscrucial to
improve healthoutcomes.Hypertensionisthe keyriskfactorforstroke;accordingto the National
Stroke Association(NSA),two-thirdsof patientswhosufferastroke have hypertension.
Hypertensionitself doesnotmanifestanysymptoms,butdirectdamage canoccur to variousorgansdue
to highbloodpressure.Incasesof hypertensive emergency(where bloodpressureishigherthan
180/110mmHg) patientshave reportedheadaches,breathlessnessormalaise due toheartfailure and
kidneyfailure.Whethersymptomaticorasymptomatic,hypertensionrequiresattentionandappropriate
changesinlifestyle ormedical treatment
The marketedproductslandscape forhypertensioncomprisesawide range of treatmentoptions,which
includesangiotensinconvertingenzyme inhibitors,angiotensinreceptorblockers,calciumchannel
blockers,betablockers,renininhibitors,anddiuretics.These are usedbothasmonotherapyand
combinationtherapy(includingfixed-dose combinations),andthe proportionof patientstreatedusing
the varioustherapyapproachesvariesfromcountrytocountry.
The highprevalence of the disease isasubstantial contributortohealthcare costsandisa majorcause
of morbidity.However,awarenessof hypertensionislow amongphysicians,patients,andthe public,
leadingtoa highlevel of undiagnosedanduntreatedcases.
Click here to find out more about this report?
2. Scope
The Asia-Pacificantihypertensive marketwill be valuedat$27 billionin2022, growingfrom$19.1 billion
in2015 at a CAGR of 5.1%. Hypertensionprevalence isaprominentcontributortomarketsize inthe
assessedcountries.The marketismostlydominatedbygenerics,andthere are onlyafew patented
products.
- Will genericscontinue todominate treatment?
- How do the elderlypopulationsandtheirassociatedriskfactorsaffectprevalence?
- What effectwill the patentexpirationsof currentlybrandedtherapieshave onmarketvalue?
The current anti-hypertensivetherapeuticspipeline isweak,comprising112 moleculesinvariousstages
of development,dominatedbysmall molecules.
- Which moleculartargetsappearmostfrequentlyinthe pipeline?
- Is there potential forthe pipelinetoaddressunmetneedswithinthe anti-hypertensive market?
Analysisof clinical trialssince2006 identifiedthatanti-hypertensiveproductshave ahighrate of
attrition.
- How do failure ratesvarybyproduct stage of development,molecule type,andmechanismof action?
- How do otherfactors suchas average trial duration andtrial size influence the costsandrisks
associatedwithproductdevelopment?
The market forecastsindicate thatJapanwill contributethe mosttothe Asia-Pacificmarketvalue,due
to the highannual cost of therapy.Growthinmarketsize isprojectedtovaryconsiderablyacrossthe
five assessedmarkets.
- How will the annual costof therapyandmarketsize varybetweenthe five Asia-Pacificmarkets?
- How couldchangesinrisk factorssuch as agingpopulation,metabolicdisordersandhighsaltintake
influencethe market?
- Variousdriversandbarrierswill influence the marketoverthe forecastperiod.
- What are the barriersthat limitthe uptake of premium-pricedtherapeuticsinthe assessedcountries?
- Which factorsare most likelytodrive the marketinthese countries?
Get Free Sample Report
3. Click here for Discounts
Reasons to buy
Thisreportwill allowyouto -
- Understandthe currentclinical andcommercial landscape byconsideringdiseasepathogenesis,
diagnosis,prognosis,andthe treatmentoptionsavailable ateachstage of diagnosis,includingaclinical
comparisonof marketedtherapies.
- Visualizethe compositionof the anti-hypertensive marketintermsof the dominanttherapies,and
theirclinical andcommercial standing.Unmetneedsare highlightedtoallow acompetitive
understandingof gapsinthe market.
- Analyze the anti-hypertensive pipelineandstratifypipeline therapiesbystage of development,
molecule type andmoleculartarget.
- Considermarketopportunitiesandpotential risksbyexaminingtrendsinhypertensionclinical trial
size,duration,andfailure rate bystage of development,moleculetype,andmechanismof action.
- Predictanti-hypertensive marketgrowthinthe five Asia-Pacificmarketswithepidemiological and
annual cost of therapyforecastsacross India,China,Australia,SouthKoreaand Japan.The forecastswill
provide anunderstandingof howepidemiologytrends,new drugentries,andpatentexpirationswill
influencemarketvalue.
- Identifycommercial opportunitiesinthe anti-hypertensivedealslandscape byanalyzingtrendsin
licensingandco-developmentdeals.
Table of Contents
1.1 Listof Tables7
1.2 Listof Figures7
2 Introduction9
2.1 Disease Introduction9
2.2 Epidemiology10
2.3 Symptoms11